<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://www.rasmusen.org/rasmapedia/index.php?action=history&amp;feed=atom&amp;title=Nondisclosure_Agreements</id>
	<title>Nondisclosure Agreements - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://www.rasmusen.org/rasmapedia/index.php?action=history&amp;feed=atom&amp;title=Nondisclosure_Agreements"/>
	<link rel="alternate" type="text/html" href="https://www.rasmusen.org/rasmapedia/index.php?title=Nondisclosure_Agreements&amp;action=history"/>
	<updated>2026-04-15T21:17:25Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.32.0</generator>
	<entry>
		<id>https://www.rasmusen.org/rasmapedia/index.php?title=Nondisclosure_Agreements&amp;diff=1961&amp;oldid=prev</id>
		<title>Rasmusen p1vaim: Blanked the page</title>
		<link rel="alternate" type="text/html" href="https://www.rasmusen.org/rasmapedia/index.php?title=Nondisclosure_Agreements&amp;diff=1961&amp;oldid=prev"/>
		<updated>2021-04-07T13:48:04Z</updated>

		<summary type="html">&lt;p&gt;Blanked the page&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #222; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #222; text-align: center;&quot;&gt;Revision as of 13:48, 7 April 2021&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot; &gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;==Vaccine Production Violations==&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt; [https://www.nytimes.com/2021/04/06/us/covid-vaccines-emergent-biosolutions.html  &amp;quot;U.S. Bet Big on Covid Vaccine Manufacturer Even as Problems Mounted,&amp;quot;] New York Times (2021)&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;blockquote style=&amp;quot;color: gray&amp;quot;&amp;gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;He added, “Any allegation that our safety, quality and compliance systems are not working or that we do not take these responsibilities seriously is false.”&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;But four former company officials, speaking on the condition of anonymity because they had signed nondisclosure agreements or feared retaliation, described an environment where top Emergent leadership tolerated and even encouraged the flouting of federal standards for manufacturing and marketing products.&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;color: #222; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;One of the former officials said that as the company scrambled to meet the heavy demands of vaccine production, a senior manufacturing supervisor often responded to reports of quality errors by asking: “Do you want me to make drugs or fix issues? I don’t have time to do both.”  &amp;lt;/blockquote&amp;gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Rasmusen p1vaim</name></author>
		
	</entry>
	<entry>
		<id>https://www.rasmusen.org/rasmapedia/index.php?title=Nondisclosure_Agreements&amp;diff=1959&amp;oldid=prev</id>
		<title>Rasmusen p1vaim: Created page with &quot;==Vaccine Production Violations==  [https://www.nytimes.com/2021/04/06/us/covid-vaccines-emergent-biosolutions.html  &quot;U.S. Bet Big on Covid Vaccine Manufacturer Even as Proble...&quot;</title>
		<link rel="alternate" type="text/html" href="https://www.rasmusen.org/rasmapedia/index.php?title=Nondisclosure_Agreements&amp;diff=1959&amp;oldid=prev"/>
		<updated>2021-04-07T13:44:42Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;==Vaccine Production Violations==  [https://www.nytimes.com/2021/04/06/us/covid-vaccines-emergent-biosolutions.html  &amp;quot;U.S. Bet Big on Covid Vaccine Manufacturer Even as Proble...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;==Vaccine Production Violations==&lt;br /&gt;
 [https://www.nytimes.com/2021/04/06/us/covid-vaccines-emergent-biosolutions.html  &amp;quot;U.S. Bet Big on Covid Vaccine Manufacturer Even as Problems Mounted,&amp;quot;] New York Times (2021)&lt;br /&gt;
&amp;lt;blockquote style=&amp;quot;color: gray&amp;quot;&amp;gt;&lt;br /&gt;
He added, “Any allegation that our safety, quality and compliance systems are not working or that we do not take these responsibilities seriously is false.”&lt;br /&gt;
&lt;br /&gt;
But four former company officials, speaking on the condition of anonymity because they had signed nondisclosure agreements or feared retaliation, described an environment where top Emergent leadership tolerated and even encouraged the flouting of federal standards for manufacturing and marketing products.&lt;br /&gt;
&lt;br /&gt;
One of the former officials said that as the company scrambled to meet the heavy demands of vaccine production, a senior manufacturing supervisor often responded to reports of quality errors by asking: “Do you want me to make drugs or fix issues? I don’t have time to do both.”  &amp;lt;/blockquote&amp;gt;&lt;/div&gt;</summary>
		<author><name>Rasmusen p1vaim</name></author>
		
	</entry>
</feed>